Barbara Klencke

Barbara Klencke

Company: Sierra Oncology

Job title: Chief Development Officer

Seminars:

Speaker Q&A panel 4:00 pm

Read more

day: Day Two

Momelotinib as a Differentiated JAK / ACBR – ACBR 1 Inhibition 3:35 pm

Describing the significant unmet needs in myelofibrosis include the need for durable benefits and longer survival, improved anemia and transfusion requirements, and benefit in patients with thrombocytopenia Detailing how potent inhibition of ACVR1, in addition to JAK1 and JAK2 inhibition, can reduce or eliminate the need for transfusion, potentially leading to improved overall survival Based…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.